ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >NELFINAVIR

NELFINAVIR

NELFINAVIR Suppliers list
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: 86-18523575427
Email: sales@conier.com
Products Intro: Product Name:nelfinavir
CAS:159989-64-7
Purity:0.99 Package:1kg
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel:
Email: 1012@dideu.com
Products Intro: Product Name:Nelfinavir
CAS:159989-64-7
Purity:99% Package:1KG;0.01USD|25KG;0.1USD|200KG;1USD
Company Name: Target Molecule Corp
Tel: 781-999-5354
Email: marketing@targetmol.com
Products Intro: Product Name:Nelfinavir;AG1341
CAS:159989-64-7
Purity:98.00% Package:5 mg;10 mg;25 mg;50 mg;100 mg;1 mL * 10 mM (in DMSO);2 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Career Henan Chemica Co
Tel: 0371-86658258
Email: Laboratory@coreychem.com
Products Intro: Product Name:NELFINAVIR
CAS:159989-64-7
Purity:85.0-99.8% Package:1KG;1USD
Company Name: Hefei TNJ Chemical Industry Co.,Ltd.
Tel: 0551-65418671
Email: sales@tnjchem.com
Products Intro: Product Name:Nelfinavir
CAS:159989-64-7

Lastest Price from NELFINAVIR manufacturers

  • Nelfinavir
  • US $0.01-1.00 / KG
  • 2020-05-03
  • CAS:159989-64-7
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 50 tons
NELFINAVIR Basic information
Product Name:NELFINAVIR
Synonyms:Nelfinavir Regeoisomer;N-tert-butyl-2-[2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide;AG 1341; AG-1341; AG1341;3-isoquinolinecarboxamide,n-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hy;8a-beta))-a-bet;nefinavir;NELFINAVIR;(3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide
CAS:159989-64-7
MF:C32H45N3O4S
MW:567.78
EINECS:1533716-785-6
Product Categories:peptides
Mol File:159989-64-7.mol
NELFINAVIR Structure
NELFINAVIR Chemical Properties
Melting point 185-186 °C
alpha D -119.23° (c = 0.26 in methanol)
Boiling point 786.8±60.0 °C(Predicted)
density 1.22±0.1 g/cm3(Predicted)
pkapKa1 6.0; pKa2 11.06(at 25℃)
Water Solubility 7g/L(temperature not stated)
Safety Information
MSDS Information
NELFINAVIR Usage And Synthesis
UsesAntiviral.
DefinitionChEBI: An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.
IndicationsNelfinavir (Viracept) is probably the most commonly used protease inhibitor because of its low incidence of serious adverse effects. Its most common side effects are diarrhea and flatulence; these may resolve with continued use. In addition to the drugs contraindicated for use with all protease inhibitors, amiodarone, rifampin, and quinidine are contraindicated in patients taking nelfinavir.
Brand nameViracept (Agouron).
Antimicrobial activityNelfinavir inhibits HIV-1 and HIV-2 proteases. Bioavailability is affected to only a limited degree by combination with lowdose ritonavir.
Acquired resistanceResistance is most frequently selected through a D30N mutation in the HIV protease. An L90M mutation also confers resistance.
Pharmaceutical ApplicationsA synthetic chemical formulated as the mesylate for oral administration.
PharmacokineticsOral absorption: c. 70–80% (with food)
Cmax 750 mg thrice daily: c. 3–4 mg/L
1250 mg twice daily: c. 4 mg/L
Cmin 750 mg thrice daily: c. 1–3 mg/L
1250 mg twice daily: c. 0.7–2.2 mg/L
Plasma half-life: c. 3.5 h
Volume of distribution: c. 2–7 L/kg
Plasma protein binding: >98%
Absorption and distribution
Food improves the bioavailability and the drug should be administered with a light meal. The semen:plasma ratio is 0.07. It is distributed into breast milk.
Metabolism and excretion
One major and several minor oxidative metabolites are found in plasma. Most of an oral dose is recovered in feces as unchanged drug (22%) and metabolites (78%). The remainder is recovered in urine, mainly unchanged.
An increase in the area under the time–concentration curve (AUC) has been observed in patients with hepatic impairment, but specific dose recommendations have not been made.
Clinical UseTreatment of HIV infection (in combination with other antiretroviral drugs)
Side effectsThe most common adverse effect is diarrhea of mild to moderate severity. Other side effects include nausea, fatigue, vomiting and headache. It is associated with less dyslipidemia in comparison with ritonavir-boosted protease inhibitors.
MetabolismFollowing oral administration, nelfinavir peak levels in plasma ranged from 0.34 mg/mL (10 mg/kg in the dog) to 1.7 mg/mL (50 mg/kg in the rat). In the dog, nelfinavir was slowly absorbed, and bioavailability was 47%. The drug appeared to be metabolized in the liver, and the major excretory route was in feces.
NELFINAVIR Preparation Products And Raw materials
Tag:NELFINAVIR(159989-64-7) Related Product Information
Ritonavir Nelfinavir RegeoisoMer (IMpurity D) (3S,4aS,8aS)-N-(1,1-DiMethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-Methylbenzoyl)aMino]-4-(phenylsulfonyl)butyl]-3-isoquinolinecarboxaMide Nelfinavir Related Compound A (15 mg) ((3S,4aS,8aS)-N-tert-Butyl-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylsulfinyl)butyl]decahydroisoquinoline-3-carboxamide) Dexrazoxane Atazanavir Telithromycin NICKEL AND VANADIUM IN RESIDUAL FUEL OIL Decahydroisoquinoline Intermediate For Nelfinavir,N-Benzyloxycarbonyl-S-Phenyl-L-Cysteine *(Intermediate of Nelfinavir) NELFINAVIR(SUBJECTTOPATENTFREE) NELFINAVIR MESYLATES NELFINAVIR MESYLATE,Nelfinavir1,Nelfinavir nesylate Decahydro- 3 –Isoquinoline Carboxamide Mono Benzoate, Nelfinavir Mesylate, NELFINAVIR-D3 AKOS 92069 NELFINAVIR HYDROXY-TERT-BUTYLAMIDE NELFINAVIR